BIOCORP and Roche Diabetes Care France announced the launch in France of Mallya, a medical device available in pharmacies. Developed by BIOCORP, this smart insulin pen device collects and transfers insulin data with near 100% accuracy. Rechargeable via its USB port, Mallya is compatible with most disposable insulin pens. This innovation aims to simplify the daily life of patients with diabetes undergoing insulin therapy, and could help avoid errors or oversights. Healthcare companies BIOCORP and Roche Diabetes Care France are finalizing their collaboration - announced last June - with the distribution of Mallya smart devices for insulin injection pens since the beginning of April. Manufactured in Clermont-Ferrand (France), this innovation for patients taking insulin is the first in its category to receive the CE-mark (medical device). Reusable and compatible with 91% of disposable insulin pens, Mallya automatically collects insulin data (dose, date, time) and transfers it to the Gluci-Chek application developed by Roche Diabetes Care France, ensuring qualified information on which the patient can rely and the physician can then make decisions3. With integration into the Roche Diabetes Care France digital ecosystem, patients benefit from solutions that lighten the mental burden of their disease, in a context where more than 750,000 people are treated with insulin injections in France (excluding insulin pumps).